The recent pullback in Hims & Hers Health (HIMS) from $27 to $19 represents a high-conviction buying opportunity, as the sell-off is driven by broader market volatility rather than company fundamentals. Trading at just 2x forward gross profit with 90% recurring revenue, the stock is undervalued for a business expanding into high-demand sectors like GLP-1 weight loss, peptides, and hormone replacement therapy. Investors should look toward the H2 2026 Eucalyptus acquisition, which is expected to add $450M in annual recurring revenue, as a major mid-term catalyst. While traditional healthcare providers like Oscar Health (OSCR) are raising prices by 30%, HIMS is positioned to capture market share as the low-cost leader in "consumerized" medicine. For those with a long-term horizon toward 2030, this entry point offers exposure to a disruptive telehealth platform that functions more like an essential subscription service than a discretionary expense.

Hims & Hers Health, Inc. (HIMS)

The stock has recently experienced a significant pullback, dropping from $27 to approximately $19 in a two-week period. The speaker argues that this sell-off is disconnected from the company's actual performance and is instead driven by broader market volatility and geopolitical tensions in the Middle East.

• Market Disconnect: The speaker highlights that while other growth stocks like SoFi might have a logical (if weak) link to interest rates and inflation, HIMS has no direct exposure to Middle East conflicts.
• Low-Cost Leader: HIMS is positioned as a "low-cost leader" in telehealth. The service eliminates the "ping pong" effect of traditional healthcare (multiple doctor visits, unpredictable insurance codes, and high out-of-pocket costs).
• Essential "Subscription" Nature: The speaker compares HIMS to Netflix, but argues it is more essential. Customers are less likely to cancel erectile dysfunction (ED), hair loss, or weight loss treatments than a streaming service.
• Key Product Catalysts:
  • GLP-1s (Weight Loss): The partnership for branded GLP-1s is back. The speaker praises the UI/UX of the website, calling it a "jewelry of marketing" that makes the product highly accessible.
  • Peptides: HIMS recently acquired a manufacturing facility in Menlo Park (formerly CS Bio) to produce peptides, signaling a major upcoming product expansion.
  • Hims Labs: A new subscription offering ($349/year) providing comprehensive blood work and biomarkers twice a year, which would typically cost thousands out-of-pocket.
  • HRT & Cancer Screening: Expansion into Hormone Replacement Therapy and the Grail cancer screening test (out-of-pocket only).
• Financial Valuation:
  • The speaker notes a history of "sandbagging" (under-promising) on guidance.
  • Eucalyptus Acquisition: Expected to close in H2 2026, adding roughly $450M in Annual Recurring Revenue (ARR).
  • Multiples: Trading at roughly 2x forward gross profit, which the speaker considers "dirt cheap" for a subscription business with 90% recurring revenue.

Takeaways

• Bullish Sentiment: The speaker views the current price of $19 as a major buying opportunity, suggesting the market is treating the stock like a "casino" rather than valuing its fundamentals.
• Growth Projections: While official guidance is lower, the speaker suggests a 50% growth scenario for 2026 is possible given the GLP-1 and peptide catalysts.
• Long-term Horizon: The speaker emphasizes a 2030 and beyond investment timeline, viewing the current decade as highly volatile and prone to "black swan" events.
• Risk Factor: The primary risk mentioned is the "trad" (traditional) market preference for established companies like Walmart or AT&T, which leads to aggressive sell-offs in high-growth "disruptor" stocks regardless of their individual success.

Other Mentioned Assets

SoFi Technologies (SOFI)

• Mentioned as a fellow growth stock that has sold off. The speaker notes that while high interest rates might logically hurt SoFi's lending business, the market is selling it off as part of a general "growth basket."

Oscar Health (OSCR)

• Mentioned in the context of the broader healthcare crisis. Oscar is reportedly raising prices by 30% across the board, which the speaker believes will drive more uninsured or under-insured customers toward the lower-cost HIMS platform.

Novo Nordisk (NVO)

• Referenced regarding the partnership and the "Novo Peel" launch. The speaker notes that the market has erased all gains HIMS made from the initial Novo partnership news, despite the partnership remaining intact.

Investment Themes & Sectors

Telehealth & "Consumerized" Medicine

• The "Enhanced Self" Trend: There is a cultural shift from "no pills is best" to "the best version of yourself is an enhanced version." HIMS is leading this by marketing pills for ED, hair loss, and longevity as lifestyle products.
• Disruption of Traditional Insurance: As out-of-pocket costs for traditional insurance rise (averaging $2,400/year), HIMS offers a way to manage specific health issues for less than the cost of a typical insurance deductible.

The "Growth vs. Trad" Divide

• Market Sentiment: The speaker observes a deep divide where "Normie" investors are flocking to "Traditional" (Trad) stocks (Retail, Telco, Big Pharma) while abandoning high-growth tech and telehealth companies, creating a valuation gap.